Free "LabXchange" science education accelerator launched by Amgen Foundation and Harvard's Faculty of Arts and Sciences

AmgenThe Amgen Foundation and the Faculty of Arts and Sciences at Harvard University (Harvard FAS) today announced the global launch of LabXchange™, a free online science education platform that provides users with access to personalized instruction, virtual lab experiences and networking opportunities across the global scientific community. LabXchange is purpose-built to drive more inclusion in the scientific process and spark collaboration to build creative, team-based approaches to real-world problems.

"Too many high school and college students lack the opportunity to directly explore the scientific process - where you build a hypothesis, understand a method, and determine how to apply it to an appropriate experimental problem," said Robert Lue, Ph.D., principal investigator of LabXchange and professor of the Practice of Molecular and Cellular Biology at Harvard. "For many students, science can feel like a collection of facts to memorize - which is contrary to what the scientific process is - it's a journey that requires bold thinking and deep imagination. With LabXchange, more students can come together and experience the joy of discovery."

Featuring virtual lab experiments developed at LabXchange along with other world-class assets created by validated partners, LabXchange brings the scientific process to life. By simulating key techniques in molecular and cellular biology, like using CRISPR to correct genetic defects, students can explore a wide range of scientific methods and build their acumen in harnessing science to solve real-life problems.

"Everyone needs science, and science needs everyone," said Robert A. Bradway, chairman and chief executive officer at Amgen. "At a time of remarkable scientific progress, we're excited by the potential of LabXchange to educate and inspire both students and lifelong learners of all ages."

LabXchange is designed to level the playing field for students and to promote science literacy for all. Key features of LabXchange include:

  • Free access to a library of world-class educational content including videos, interactive simulations and assessments.
  • Ability to mix and match materials, empowering teachers to create flexible learning pathways for classes or individual students that complement existing science curriculums.
  • Global networking functionality, enabling teachers to collaborate beyond a single classroom, school or district.

LabXchange builds upon other Amgen Foundation programs that support science education, such as the Amgen Biotech Experience and Amgen Scholars that are also at Harvard FAS and institutions around the world. To date, the Foundation has contributed more than $150 million to advancing science education programming globally as part of its mission to facilitate global collaboration on the United Nations Sustainable Development Goals (SDGs), notably SDG #4 on Quality Education, but also SDG #3 on Good Health and Well-Being.

For more information, please visit www.LabXchange.org.

About the Amgen Foundation

The Amgen Foundation seeks to advance excellence in science education to inspire the next generation of innovators, and invest in strengthening communities where Amgen staff members live and work. To date, the Foundation has donated over $300 million to local, regional, and international non-profit organizations that impact society in inspiring and innovative ways. The Amgen Foundation brings the excitement of discovery to the scientists of tomorrow through several signature programs, including Amgen Scholars and the Amgen Biotech Experience.

About Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

Scientists develop new biomimetic formulation for …

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore ...